Now Live The BioInsights Podcast Modernizing cell therapy manufacturing to reduce vein-to-vein timesListen now
Recovering More High-Quality Cells
DCS Processing consistently recovers more WBC than other technologies, featuring an average recovery of ~90% combined with an industry leading low variability (<7%Coefficient of Variation)
DCS processing maintains cell viability to within 1% of input viability. Viability typically exceeds centrifugal methods.
Superior Removal of Contaminants
DCS' unique separation mechanism of enables robust removal of RBCs from fresh Leukopacks, leaving essentially RBC free PBMC for next step in the engineering process.
DCS platelet removal efficiency is in excess of 99%. This near complete elimination of biological drivers from activated platelets ensures that DCS processed cells are uniquely well positioned for next steps in the manufacturing journey.
Note: All data based on Curate System prototype. (N=54)
DCS™ (Deterministic Cell Separation™ – Curate Microfluidics Platform)